0001735276-23-000006.txt : 20230203 0001735276-23-000006.hdr.sgml : 20230203 20230203174542 ACCESSION NUMBER: 0001735276-23-000006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230201 FILED AS OF DATE: 20230203 DATE AS OF CHANGE: 20230203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tanguler Tolga CENTRAL INDEX KEY: 0001849458 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36407 FILM NUMBER: 23587614 MAIL ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001178670 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770602661 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 551-8200 MAIL ADDRESS: STREET 1: 675 WEST KENDALL STREET STREET 2: HENRI A. TERMEER SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020724 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2023-02-01 0 0001178670 ALNYLAM PHARMACEUTICALS, INC. ALNY 0001849458 Tanguler Tolga 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2023-02-01 4 M 0 5025 0.0 A 5025 D Common Stock 2023-02-02 4 S 0 73 223.97 D 4952 D Common Stock 2023-02-02 4 S 0 963 225.8 D 3989 D Common Stock 2023-02-02 4 S 0 561 226.62 D 3428 D Common Stock 2023-02-02 4 S 0 4 227.38 D 3424 D Common Stock 2023-02-03 4 S 0 128 227.68 D 3296 D Common Stock 2023-02-03 4 S 0 185 230.2 D 3111 D Common Stock 2023-02-03 4 S 0 865 231.35 D 2246 D Common Stock 2023-02-03 4 S 0 1293 232.53 D 953 D Common Stock 2023-02-03 4 S 0 953 233.31 D 0 D Restricted Stock Units 0.0 2023-02-01 4 M 0 5025 0.0 D Common Stock 5025 0 D Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.42 to $224.25. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $225.21 to $226.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.23 to $227.12. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.63 to $228.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.87 to $230.62. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.90 to $231.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.94 to $232.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.02 to $233.81. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. On February 1, 2021 the reporting person received 10,051 restricted stock units, one-half of which vested on the first anniversary of the grant date, and one-half of which vested on the second anniversary of the grant date (February 1, 2023). By: /s/ Cynthia L Anderson, Attorney-in-Fact For: Tolga Tanguler 2023-02-03